Page last updated: 2024-09-05

s 16020-2 and Sensitivity and Specificity

s 16020-2 has been researched along with Sensitivity and Specificity in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Awada, A; Bleiberg, H; Brillanceau, MH; Calvo, F; De Valeriola, D; Dosquet, C; Eftekhary, P; Gerard, B; Giacchetti, S; Giroux, B; Lucas, C; Marty, M; Piccart, M; Poullain, MG; Soudon, J	1

Trials

1 trial(s) available for s 16020-2 and Sensitivity and Specificity

Article	Year
Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedules. Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:12 Topics: Adult; Aged; Biological Availability; Carbazoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Ellipticines; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyridines; Risk Assessment; Sensitivity and Specificity; Treatment Outcome	2002

Article

Year

Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedules.

Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:12

Topics: Adult; Aged; Biological Availability; Carbazoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Ellipticines; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyridines; Risk Assessment; Sensitivity and Specificity; Treatment Outcome

2002